

## NeuroMetrix Announces Broad SENSUS Distribution Agreement with DJO Global

WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (the "Company") (Nasdaq: NURO), a medical device company focused on the treatment and management of the neurological complications of diabetes, today announced a national distribution agreement with DJO Global for the SENSUS™ Pain Management System. SENSUS is a convenient and wearable non-invasive electrical nerve stimulator that offers patients a fast-acting, non-narcotic option for relief from chronic pain. The device is lightweight and can be worn during the day while remaining active, or at night while sleeping. It is optimally designed for people with diabetes that suffer from chronic pain. The most common cause of such pain is painful diabetic neuropathy (PDN), which affects up to 5 million people in the U.S. alone.

The Recovery Sciences division of DJO is a leading manufacturer and distributor of electrical stimulation and other orthopedic products used for pain management, orthopedic rehabilitation, physical therapy, fitness and sport performance enhancement. It deploys a direct US sales force. Recovery Sciences will market SENSUS primarily to pain management and podiatry clinics, as well as in endocrinology, internal medicine, primary care and neurology clinics. This agreement follows a SENSUS market pilot conducted in the second half of 2013.

"SENSUS nicely compliments the Recovery Sciences electrotherapy product offerings for pain management", said Rick Rioles, Senior Vice President, Business Development, Recovery Sciences Division, DJO Global. "We believe that the diabetic pain market represents a growth opportunity for electrotherapy as it addresses important unmet clinical needs. We are impressed by the SENSUS technology and its status as the only transcutaneous electrical nerve stimulator cleared for use during sleep. We believe it will have strong appeal in our target markets."

"DJO Global is a leader in the pain management market. The Recovery Sciences division includes EMPI, which is a long standing premier brand in the transcutaneous electrical nerve stimulator market. We believe that the national reach, talent, and subject matter expertise of the Recovery Sciences sales force will play a key role in accelerating SENSUS adoption in the US market," said Shai N. Gozani, M.D., Ph.D., President and Chief Executive Officer of NeuroMetrix. "We believe that this partnership will substantially expand patient access to the clinical benefits of SENSUS pain therapy."

### About DJO Global, Inc.

DJO Global, Inc. is a leading global provider of high-quality, orthopedic devices, with a broad range of products used for rehabilitation, pain management and physical therapy. It also develops, manufactures and distributes a broad range of surgical reconstructive implant products. DJO Global is the largest non-surgical orthopedic rehabilitation device company in the United States and among the largest globally, as measured by revenues. For more information, please visit <http://www.djoglobal.com>.

### About NeuroMetrix

NeuroMetrix is a medical device company that develops and markets home use and point-of-care devices for the treatment and management of chronic pain, peripheral neuropathies, and associated neurological disorders. The Company is presently focused on diabetic neuropathies, which affect over 50% of people with diabetes. If left untreated, diabetic neuropathies trigger foot ulcers that may require amputation and cause disabling chronic pain. The annual cost of diabetic neuropathies has been estimated at \$14 billion in the United States. The company markets the SENSUS™ Pain Management System for treating chronic pain, focusing on physicians managing patients with painful diabetic neuropathy.

The company also markets the DPNCheck® device, which is a rapid, accurate, and quantitative point-of-care test for diabetic neuropathy. This product is used to detect diabetic neuropathy at an early stage and to guide treatment. For more information, please visit <http://www.SENSUSRx.com>.

NeuroMetrix, Inc.  
Thomas T. Higgins, 781-314-2761  
SVP and Chief Financial Officer  
[neurometrix.ir@neurometrix.com](mailto:neurometrix.ir@neurometrix.com)

Source: NeuroMetrix, Inc.

